Creatine Supplementation During GLP-1a Therapy
2026年5月30日 更新者:Phil Chilibeck、University of Saskatchewan
A Pilot Study on Creatine Supplementation During Resistance-training for Prevention of Lean Tissue Mass Loss During GLP-1 Receptor Agonist Therapy
GLP-1 receptor agonists are effective for weight loss, but significant muscle mass is lost as a proportion of this weight loss.
This study combines resistance-training and creatine supplementation to try to prevent this loss of muscle mass.
研究概览
地位
招聘中
条件
详细说明
GLP-1 receptor agonists are highly effective for weight loss and increasing in popularity for those trying to lose weight.
One concern with these medications is the potential for loss of lean tissue mass during rapid weight loss.
This may affect strength and functional performance in people taking these medications.
Resistance-training helps to offset loss of muscle mass during weight loss.
Supplementation with creatine monohydrate is also effective for improving muscle mass and strength.
The purpose of this pilot study is to determine the effectiveness of creatine supplementation during a resistance training program in people who are starting GLP-receptor agonist medication for preventing loss of lean tissue mass and functional performance.
The investigators will randomize 40 people who are starting GLP-1 agonists to receive either 10g per day creatine or placebo during a resistance-training program (i.e., resistance-training three days per week for 12 weeks).
It is hypothesized that participants on the creatine supplement will have superior maintenance of lean tissue mass and function performance compared to participants taking placebo.
研究类型
介入性
注册 (估计的)
40
阶段
- 不适用
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Philip D Chilibeck, PhD
- 电话号码:306-966-1072
- 邮箱:phil.chilibeck@usask.ca
学习地点
-
-
SK - Saskatchewan
-
Saskatoon、SK - Saskatchewan、加拿大、S7N 5B2
- 招聘中
- University of Saskatchewan
-
接触:
- Philip D Chilibeck, PhD
- 电话号码:306-966-1072
- 邮箱:phil.chilibeck@usask.ca
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
是的
描述
Inclusion Criteria:
- Starting GLP-1 agonist therapy
- 18 years of age or older
Exclusion Criteria:
- Positive answers to a screening questionnaire for physical activity safety (the Get Active Questionnaire)
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:预防
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:四人间
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
安慰剂比较:安慰剂
安慰剂(麦芽糖糊精)
|
Placebo
|
|
实验性的:Creatine
10 grams per day creatine
|
creatine supplementation
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in sit to stand performance (number of times)
大体时间:12 weeks
|
change in number of times sitting and standing in 30 seconds
|
12 weeks
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Change in 10 meter gait speed (m/s)
大体时间:12 weeks
|
change in walking speed over 10 meters
|
12 weeks
|
|
Change in timed up and go (m/s)
大体时间:12 weeks
|
change in time to stand up, walk 3m, turn, around, walk 3 m and sit down
|
12 weeks
|
|
Change in lean tissue mass (kg)
大体时间:12 weeks
|
Change in lean tissue mass as determined by dual energy x-ray absorptiometry
|
12 weeks
|
|
Change in fat mass (kg)
大体时间:12 weeks
|
Change in fat mass as determined by dual energy x-ray absorptiometry
|
12 weeks
|
|
Change in whole body bone mineral density (g/cm squared)
大体时间:12 weeks
|
Change in bone mineral density as determined by dual energy x-ray absorptiometry
|
12 weeks
|
|
Change in femoral neck bone mineral density (g/cm squared)
大体时间:12 weeks
|
Change in bone mineral density as determined by dual energy x-ray absorptiometry
|
12 weeks
|
|
Change in total hip bone mineral density (g/cm squared)
大体时间:12 weeks
|
Change in bone mineral density as determined by dual energy x-ray absorptiometry
|
12 weeks
|
|
Change in lumbar spine bone mineral density (g/cm squared)
大体时间:12 weeks
|
Change in bone mineral density as determined by dual energy x-ray absorptiometry
|
12 weeks
|
|
Change in hip section modulus (cm-cubed)
大体时间:12 weeks
|
Change in hip section modulus as determined by dual energy x-ray absorptiometry
|
12 weeks
|
|
Change in muscle thickness of the biceps (cm)
大体时间:12 weeks
|
Change in muscle thickness measured by ultrasound
|
12 weeks
|
|
Change in muscle thickness of the quadriceps (cm)
大体时间:12 weeks
|
Change in muscle thickness measured by ultrasound
|
12 weeks
|
|
Change in bench press strength (kg)
大体时间:12 weeks
|
change in upper body strength measured by predicted one repetition maximum
|
12 weeks
|
|
Change in leg extension strength (kg)
大体时间:12 weeks
|
Change in lower body strength measured by predicted one repetition maximum
|
12 weeks
|
|
Change in hip buckling ratio (ratio)
大体时间:12 weeks
|
Change in hip buckling ratio as determined by dual energy x-ray absorptiometry
|
12 weeks
|
|
Change in hip cross-sectional area (cm-squared)
大体时间:12 weeks
|
Change in hip cross-sectional area as determined by dual energy x-ray absorptiometry
|
12 weeks
|
|
Change in hip cortical thickness (cm)
大体时间:12 weeks
|
Change in hip cortical thickness as determined by dual energy x-ray absorptiometry
|
12 weeks
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 首席研究员:PHILIP Chilibeck, PhD、University of Saskatchewan
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年5月25日
初级完成 (估计的)
2027年5月30日
研究完成 (估计的)
2027年12月31日
研究注册日期
首次提交
2026年5月25日
首先提交符合 QC 标准的
2026年5月30日
首次发布 (实际的)
2026年6月4日
研究记录更新
最后更新发布 (实际的)
2026年6月4日
上次提交的符合 QC 标准的更新
2026年5月30日
最后验证
2026年5月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.